Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters










Database
Language
Publication year range
2.
Gene ; 589(2): 127-32, 2016 Sep 10.
Article in English | MEDLINE | ID: mdl-26143115

ABSTRACT

A "cancer predisposing syndrome" later labeled as Hereditary Non-Polyposis Colorectal Cancer (HNPCC) or Lynch Syndrome, was firstly described by Warthin, about one century ago. An increased predisposition to the development of multiple familial tumors is described as characteristic of this syndrome where visceral and cutaneous malignancies may appear at an early age namely endometrial, gastric, small bowel, ureteral and renal pelvis, ovarian, hepatobiliary tract, pancreatic, brain (Turcot Syndrome) and sebaceous glands (Muir-Torre Syndrome). The latter, a variant of Lynch Syndrome, is characterized by the presence of sebaceous skin adenomas, carcinomas and/or keratoacanthomas associated with visceral malignancies. Both Lynch Syndrome and Muir-Torre Syndrome have been recognized due to germline mutations in mismatch repair genes MLH1, MSH2 and MSH6. To date, 56 Lynch Syndrome founder mutations dependent on MLH1, MSH2 and, although less frequently found, MSH6 and PMS2 are described. Some of these founder mutations, principally of MSH2 gene, have been described to cause Muir-Torre phenotype and have been traced in large and outbreed Muir-Torre Syndrome families living in different US and European territories. Due to the evidences of highly specific Muir-Torre phenotypes related to the presence of widespread MSH2 founder mutations, preliminary search for these MSH2 common mutations in individuals carrying sebaceous tumors and/or keratoacanthomas, at early age or in association to visceral and familial tumors, permits cost-effective and time-saving diagnostic strategies for Lynch/Muir-Torre Syndromes.


Subject(s)
Brain Neoplasms/history , Colorectal Neoplasms, Hereditary Nonpolyposis/history , Colorectal Neoplasms/history , DNA-Binding Proteins/genetics , Muir-Torre Syndrome/history , MutL Protein Homolog 1/genetics , MutS Homolog 2 Protein/genetics , Neoplastic Syndromes, Hereditary/history , Brain Neoplasms/diagnosis , Brain Neoplasms/genetics , Brain Neoplasms/pathology , Colon/metabolism , Colon/pathology , Colorectal Neoplasms/diagnosis , Colorectal Neoplasms/genetics , Colorectal Neoplasms/pathology , Colorectal Neoplasms, Hereditary Nonpolyposis/diagnosis , Colorectal Neoplasms, Hereditary Nonpolyposis/genetics , Colorectal Neoplasms, Hereditary Nonpolyposis/pathology , Female , Founder Effect , Gene Expression , Germ-Line Mutation , History, 20th Century , History, 21st Century , Humans , Male , Mismatch Repair Endonuclease PMS2/genetics , Muir-Torre Syndrome/diagnosis , Muir-Torre Syndrome/genetics , Muir-Torre Syndrome/pathology , Neoplastic Syndromes, Hereditary/diagnosis , Neoplastic Syndromes, Hereditary/genetics , Neoplastic Syndromes, Hereditary/pathology , Pedigree , Sebaceous Glands/metabolism , Sebaceous Glands/pathology
3.
Pediatr Dev Pathol ; 18(6): 504-11, 2015.
Article in English | MEDLINE | ID: mdl-26698637

ABSTRACT

Pleuropulmonary blastoma (PPB) is the most common primary malignant neoplasm of the lung in children. Like other solid dysontogenic neoplasms, this tumor typically presents before 7 years of age. The earliest manifestation is the presence of a lung cyst(s), which is usually recognized in the first year of life and is difficult to differentiate on the basis of imaging studies from non-neoplastic cysts of early childhood. From a multilocular cyst, PPB has the potential to progress to a high-grade multipatterned primitive sarcoma. More than 65% of all affected children have a heterozygous germline mutation in DICER1. The DICER1 PPB familial tumor predisposition syndrome is initially recognized in most cases on the basis of PPB alone but also by several other unique and characteristic extrapulmonary tumors, including pediatric cystic nephroma, nasal chondromesenchymal hamartoma, nodular lesions of the thyroid, embryonal rhabdomyosarcoma of the cervix, and ciliary body medulloepithelioma.


Subject(s)
Lung Neoplasms/pathology , Neoplastic Syndromes, Hereditary/pathology , Pulmonary Blastoma/pathology , Biopsy , Child, Preschool , DEAD-box RNA Helicases/genetics , Female , Genetic Predisposition to Disease , Germ-Line Mutation , History, 20th Century , History, 21st Century , Humans , Lung Neoplasms/classification , Lung Neoplasms/genetics , Lung Neoplasms/history , Male , Neoplastic Syndromes, Hereditary/classification , Neoplastic Syndromes, Hereditary/genetics , Neoplastic Syndromes, Hereditary/history , Phenotype , Prognosis , Pulmonary Blastoma/classification , Pulmonary Blastoma/genetics , Pulmonary Blastoma/history , Ribonuclease III/genetics , Terminology as Topic , Tomography, X-Ray Computed
4.
Endocr Relat Cancer ; 22(4): T147-59, 2015 Aug.
Article in English | MEDLINE | ID: mdl-26273101

ABSTRACT

The last decades have elucidated the genetic basis of pheochromocytoma (PC) and paraganglioma (PGL) (PCPGL)-associated hereditary syndromes. However, the history of these syndromes dates back at least another 150 years. Detailed descriptions by clinicians and pathologists in the 19th and 20th centuries led to the recognition of the PCPGL-associated syndromes von Hippel-Lindau disease, neurofibromatosis type 1, and multiple endocrine neoplasia type 2. In the beginning of the current millennium the molecular basis of the hereditary PGL syndrome was elucidated by the discovery of mutations in genes encoding enzymes of the Krebs cycle, such as succinate dehydrogenase genes (SDHx) and other mutations, causing 'pseudo-hypoxia' signaling. These recent developments also marked a paradigm shift. It reversed the traditional order of genetic research that historically aimed to define the genetic basis of a known hereditary syndrome but now is challenged with defining the full clinical phenotype associated with a newly defined genetic basis. This challenge underscores the importance to learn from medical history, continue providing support for clinical research, and train physicians with regards to their skills to identify patients with PCPGL-associated syndromes to extend our knowledge of the associated phenotype. This historical overview provides details on the history of the paraganglial system and PCPGL-associated syndromes. As such, it hopefully will not only be an interesting reading for the physician with a historical interest but also emphasize the necessity of ongoing astute individual clinical observations and clinical registries to increase our knowledge regarding the full phenotypic spectrum of these conditions.


Subject(s)
Adrenal Gland Neoplasms/history , Neoplastic Syndromes, Hereditary/history , Paraganglioma/history , Pheochromocytoma/history , Animals , History, 18th Century , History, 19th Century , History, 20th Century , History, 21st Century , Humans
5.
Gesnerus ; 64(1-2): 69-92, 2007.
Article in English | MEDLINE | ID: mdl-17982960

ABSTRACT

The story of thyroid calcitonin is an illuminating example of the voyage of hormone from a therapeutic tool for bone disease to a tumour marker to screen for subclinical forms of cancer. Identified as a new thyroid hormone implicated in calcium metabolism, its pharmacological action offered a new therapeutic tool for the management of bone disease. By measuring the circulating calcitonin, a range of values was obtained for oncologists because the evolution of a newly identified form of thyroid cancer--medullary (MTC)--was poorly understood. Researchers' interest shifted from calcitonin physiological action to its use as tumour marker able to diagnose MTC, especially in genetically predisposed families. Then, oncologists and geneticists combined their efforts to identify genetic mutation(s) implicated in MTC, an example of the decoding that is demanded of contemporary laboratory-based medicine to recognise a pathological entity.


Subject(s)
Biomarkers, Tumor/history , Calcitonin/history , Carcinoma, Medullary/history , Neoplastic Syndromes, Hereditary/history , Thyroid Neoplasms/history , Europe , History, 20th Century , Humans , United States
6.
Am J Med Genet C Semin Med Genet ; 129C(1): 5-22, 2004 Aug 15.
Article in English | MEDLINE | ID: mdl-15264268

ABSTRACT

The hereditary predisposition to cancer dates historically to interest piqued by physicians as well as family members wherein striking phenotypic features were shown to cluster in families, inclusive of the rather grotesque cutaneous findings in von Recklinghausen's neurofibromatosis, which date back to the sixteenth century. The search for the role of primary genetic factors was heralded by studies at the infrahuman level, particularly on laboratory mouse strains with strong susceptibility to carcinogen-induced cancer, and conversely, with resistance to the same carcinogens. These studies, developed in the 19th and 20th centuries, continue today. This article traces the historical aspects of hereditary cancer dealing with identification and ultimate molecular genetic confirmation of commonly occurring cancers, particularly of the colon in the case of familial adenomatous polyposis and its attenuated form, both due to the APC germline mutation; the Lynch syndrome due to mutations in mismatch repair genes, the most common of which were found to be MSH2, MLH1, and MSH6 germline mutations; the hereditary breast-ovarian cancer syndrome with BRCA1 and BRCA2 germline mutations; the Li-Fraumeni (SBLA) syndrome due to the p53 mutation; and the familial atypical multiple mole melanoma in association with pancreatic cancer due to the CDKN2A (p16) germline mutation. These and other hereditary cancer syndromes have been discussed in some detail relevant to their characterization, which, for many conditions, took place in the late 18th century and, in the more modern molecular genetic era, during the past two decades. Emphasis has been placed upon the manner in which improved cancer control will emanate from these discoveries.


Subject(s)
Genetic Predisposition to Disease , Neoplasms/history , Animals , Breast Neoplasms/genetics , Breast Neoplasms/history , Colorectal Neoplasms/genetics , Colorectal Neoplasms/history , Disease Models, Animal , Female , History, 16th Century , History, 17th Century , History, 18th Century , History, 19th Century , History, 20th Century , History, 21st Century , Humans , Melanoma/genetics , Melanoma/history , Mice , Multiple Endocrine Neoplasia/genetics , Multiple Endocrine Neoplasia/history , Neoplasms/genetics , Neoplastic Syndromes, Hereditary/genetics , Neoplastic Syndromes, Hereditary/history , Neurofibromatoses/genetics , Neurofibromatoses/history , Ovarian Neoplasms/genetics , Ovarian Neoplasms/history , Pedigree
SELECTION OF CITATIONS
SEARCH DETAIL
...